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Pregnancy is associated with many physiological changes. During pregnancy, the 
pharmacokinetics of certain drugs are altered. In particular, the clearance of drugs undergoing 
glucuronidation has been reported to drastically increase during pregnancy. Pregnancy-mediated 
changes in the plasma concentrations of estrogens and progesterone have been suggested to 
influence the expression and activity of certain phase I metabolic enzymes. Limited information, 
however, is available on the effect of pregnancy-related hormones on the activity of glucuronide-
conjugating enzymes in humans. In this study, we determined the optimal conditions for 
evaluating glucuronidation in human liver microsomal systems. We also determined the effects 
of progesterone and estradiol on the expression of UGT1A9 mRNA, and the activity UGT1A9 
(formation of mycophenolic acid glucuronide (MPAG) from mycophenolic acid (MPA)) using 
primary cultures of human hepatocytes. The results showed a non-significant increase in the 
expression of UGT1A9 and in the formation of mycophenolic acid glucuronide from MPA in 
human hepatocytes treated with a combination of progesterone and estradiol. Progesterone and 
estradiol do not appear to significantly alter the metabolism of the substrates of UGT1A9. Future 
studies should evaluate additional factors that may account for the observed alterations in 
UGT1A9 activity during pregnancy. 
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1.0  INTRODUCTION 
 
Eighty-three percent of pregnant women are prescribed at least one prescription drug, with most 
of them being antibiotics or analgesics (Mitchell et al., 2011). Other frequently prescribed 
medications during pregnancy include antidepressants, antihistamines, antiepileptics, diuretics 
and medications that are used to treat pregnancy-induced conditions such as hypertension, 
gestational diabetes and emesis (Mitchell et al., 2011)  
 
Pharmacokinetics in Pregnancy 
 Pharmacokinetics of drugs are not well characterized during pregnancy because of the 
exclusion of pregnant women from clinical trials (Blackburn, 2012). Pregnancy is known to be 
associated with many physiological changes. These changes can alter the absorption, 
distribution, metabolism, and excretion of various drugs (Anderson, 2005). Several factors 
contribute to the altered absorption of drugs during pregnancy. Increased cardiac output during 
pregnancy has been associated with an increase in the rate of absorption of certain drugs from the 
gastrointestinal tract (Yaffe & Aranda, 1992). Increase in gastric pH during pregnancy tends to 
reduce absorption of weak acids and lead to increase Tmax and decrease Cmax (Dawes & 
Chowienczyk, 2001). Nausea and vomiting, which are common in pregnant women, may 
interfere with absorption of orally administered drugs (Dawes & Chowienczyk, 2001). In such 
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cases, administration of drugs via inhalation could enhance the absorption of drugs due to 
increase in cardiac output and tidal volume that leads to increase in alveoli uptake (Dawes & 
Chowienczyk, 2001). Drug absorption from the intramuscular route has been reported to be 
increased due to increased tissue blood perfusion (Dawes & Chowienczyk, 2001).  
Several factors contribute to the altered distribution of drugs during pregnancy. The 
maternal blood volume increases during pregnancy to supply the uteroplacental unit and the fetus 
(Lee, 1991; Whittaker, Macphail, & Lind, 1996). The total body water and plasma volume 
increase by approximately 50% by the end of gestation (Cunningham & Williams, 2010). These 
changes will increase the volume of distribution of hydrophilic drugs (Anderson, 2005). 
Concentrations of some of the plasma proteins (e.g., albumin and alpha-1 acid glycoprotein) are 
decreased during pregnancy resulting in an increase in the unbound fraction of highly protein-
bound drugs, and corresponding increase in the apparent volume of distribution (Anderson, 
2005) and (Little, 1999; Perucca & Crema, 1982). The drugs that are influenced to the greatest 
extent by changes in plasma protein binding are low extraction ration drugs such as phenytoin, 
and high extraction ration drugs that have a narrow therapeutic window (Anderson, 2005). In 
addition, body fat increases during pregnancy causing an increase in the volume of distribution 
of lipophilic drugs (Little, 1999). Increase in volume of distribution typically leads to a decrease 
in maximum concentrations of the drugs in plasma (Dawes & Chowienczyk, 2001).  
Pregnancy is also associated with increased clearance of certain drugs. The increase in 
renal blood flow and decrease in renal vascular resistance leads to an increase in glomerular 
filtration rate in pregnant women (Anderson, 2005; Pavek, Ceckova, & Staud, 2009). Other 
physiological changes associated with pregnancy include an increase in heart rate, blood 
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pressure, blood volume, tidal volume, gastric emptying time and other changes in other body 
systems such as the kidney and the liver (Feghali & Mattison, 2011; Hill & Pickinpaugh, 2008; 
Yeomans & Gilstrap, 2005). Drug metabolism has also been reported to be altered during 
pregnancy (Jeong, Choi, Song, Chen, & Fischer, 2008; Tracy, Venkataramanan, Glover, & 
Caritis, 2005; Tsutsumi et al., 2001).   
  Cytochrome P450 (CYPs), uridine diphosphate glucuronosyltransferases (UGTs), 
sulfonyl transferases and N-acetyltransferase (NAT) (Anderson, 2005) are some of the common 
drug metabolizing enzymes in humans. The activity of certain cytochrome P450 and UGT 
isoforms has been reported to be altered in pregnancy (Anderson, 2005; Pavek et al., 2009). The 
activity of cytochrome P450 3A4 (CYP3A4), the most highly expressed CYP enzyme in the 
human liver and gastrointestinal tract (Anderson, 2005), is increased during pregnancy (Pavek et 
al., 2009). The metabolism of methadone, nifedipine and indinavir, which are substrates of 
CYP3A4, have been reported to increase in pregnancy (Pavek et al., 2009). Likewise, 
cytochrome P450 2A6 (CYP2A6) activity increases in the second and third trimesters of 
pregnancy (Pavek et al., 2009). Clearance of nicotine and cotinin, substrates of CYP2A6, 
increases during pregnancy (Anderson, 2005; Pavek et al., 2009). The activity of cytochrome 
P450 2C9 (CYP2C9) and cytochrome P450 2D6 (CYP2D6) also increases during pregnancy 
(Anderson, 2005; Pavek et al., 2009).  A recent study has shown an increase in the activity of 
cytochrome P450 2D6 (CYP2D6) during pregnancy, which was responsible for the increased 
clearance of clonidine (Claessens et al., 2010). On the other hand, a decrease in the activity of 
cytochrome P450 1A2 (CYP1A2) in all three trimesters has also been reported (Tsutsumi et al., 
2001). The activity of cytochrome P450 1A2 (CYP1A2) decreases throughout pregnancy (Pavek 
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et al., 2009). Correspondingly, the metabolism of caffeine, a CYP1A2 probe, is decreased during 
pregnancy (Pavek et al., 2009). 
Some studies have shown an increase in glucuronidation during pregnancy (Chen, Yang, 
Choi, Fischer, & Jeong, 2009; Miners, Robson, & Birkett, 1986). UDP-glucuronosyltransferase 
1A4 (UGT1A4) is the most well-studied UGT isoform during pregnancy. Studies have shown a 
significant increase in the clearance of lamotrigine in pregnant women compared to non-pregnant 
women (Anderson, 2005; Chen et al., 2009; Pavek et al., 2009). The clearance of morphine and 
zidovudine, which are substrates of UGT2B7, has been reported to increase during pregnancy 
suggesting an increase in the activity of UGT2B7 (Pavek et al., 2009). An increase in the oral 
clearance of labetalol, which is a substrate of UGT1A1, during pregnancy, has also been reported 
(Jeong et al., 2008).  
The mechanism underlying alteration in the activity of various drug-metabolizing 
enzymes is not completely clear. Various pregnancy-related hormones have been implicated as 
potential agents that contribute to altered enzyme activity during pregnancy. Progesterone levels 
at third trimester average nearly 150 ng/ml, representing an approximately ten-fold increase over 
normal levels in menstrual cycle (Pfaff, 2002). Estradiol levels range from 10 to 15 ng/ml, 
representing a fifty-fold increase over normal levels (Pfaff, 2002). Given that the blood levels of 
female hormones such as estradiol and progesterone are increased during pregnancy, it is logical 
to expect a potential role of these hormones in regulating the metabolism and the 
pharmacokinetics of various drugs (Chen et al., 2009). Recent observations have suggested a role 
for estrogens and progesterone as regulators of altered activity of CYP enzymes in pregnancy 
(Choi, Koh, & Jeong, 2012). Nothing is known about what factors regulate the expression and 
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activity of UGTs during pregnancy. In this document, we focus on the activity of one of the 
UGTs and evaluate the role of estrogens and progesterone on the activity of the UGTs. The 
following is a brief discussion of various UGT pathways. 
UDP-glucuronosyltranserases (UGTs) are phase II metabolic enzymes that catalyze the 
conjugation of many endogenous (e.g., bilirubin, bile acids, steroid hormones, thyroid 
hormones), and exogenous compounds (e.g. mycophenolic acid, morphine, buprenorphine and 
acetaminophen) with glucuronic acid (Radominska-Pandya, Czernik, Little, Battaglia, & 
Mackenzie, 1999) (Table 1). This conjugation makes compounds more hydrophilic and 
facilitates renal and biliary excretion (Williams & Lemke, 2002). UGTs are located in the 
endoplasmic reticulum (ER) of the liver, endothelial cells of intestine and other tissues (Williams 
& Lemke, 2002). They are classified into two major groups, UGT1 and UGT2, based on 
nucleotide and amino acid sequences (Luquita et al., 2001) and are then subdivided into further 
subfamilies (King, Rios, Green, & Tephly, 2000). The major UGTs isoforms expressed in the 
liver include UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B15, 2B17 and 2B28 (Miners, Smith, 
Sorich, McKinnon, & Mackenzie, 2004). Some UGT isoforms are also expressed in other tissues 
such as lung, small intestine, kidney, olfactory epithelium, ovary, mammary gland, testis, and 
brain (Miners et al., 2004). However, UGT1A8 and UGT1A10 are expressed predominately in 
gastrointestinal tract (Mojarrabi & Mackenzie, 1998). UGT1A1 and UGT1A6 are absent from 
fetal liver, while UGT1A3 is present in fetal liver (McCarver & Hines, 2002). 
Although a majority of glucuronidated compounds are inactive, some glucuronides 
exhibit higher activity than the parent drugs (Liston, Markowitz, & DeVane, 2001). For instance, 
morphine 6- glucuronide is found to be more potent than parent drug morphine and digitoxin- 
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and digoxin- glucuronides have positive inotropic effects (Pasternak, Bodnar, Clark, & Inturrisi, 
1987; Scholz & Schmitz, 1984). Various isoforms of UGTs exhibit overlapping selectivity which 
makes studying one particular isoform somewhat difficult (Miners et al., 2004).  
An exhaustive literature search revealed that drug metabolism in general has not been 
well-studied in pregnancy; in particular, the regulation of the glucuronidation pathway has not 
been well characterized in pregnancy. Most of studies are done in animals and cannot be 
extrapolated to humans. So it is important to use a human-based system such as human 
hepatocytes or human liver microsomes. Therefore, more research on factors that regulate the 
expression and/ or the activity of UGTs is necessary in humans in order to optimize drug therapy 
in pregnancy. This study is a first attempt at characterizing the effect of estrogen and 
progesterone on the activity of UGTs using primary cultures of human hepatocytes. 
 
Selection of Method to Study UGT Activity 
 
The active site of UGT is hidden within the lumen of ER (Chang, Yoo, Lee, Klopf, & 
Takao, 2009). Therefore, the activity of UGTs in vitro exhibits latency. Disruption of the 
membrane by chemical (e.g., brij58, alamehticin) (Dutton, 1980; Engtrakul, Foti, Strelevitz, & 
Fisher, 2005; Fisher, Campanale, Ackermann, VandenBranden, & Wrighton, 2000; Kilford, 
Stringer, Sohal, Houston, & Galetin, 2009) and mechanical (e.g., sonication, freeze/thaw and 
vortexing) means have been used to characterize the activity of UGTs (Dutton, 1980). The 
activity of UGTs has been shown to be higher with such treatment (Chang et al., 2009). The most 
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widely used membrane-disturbing agents are alamethicin and brij58. Alamethicin, a pore 
forming 20 amino acid peptide (Bechinger, 1997), is widely used to study the activity of UGTs. 
It forms pores in the ER membrane, which facilitates the passage of substrate and the cofactor, 
UDP-glucuronic acid (UDPGA), through the membrane (Chang et al., 2009). Alamethicin 
showed the highest activation of UGTs compared with other tested detergents (Fisher, Paine, 
Strelevitz, & Wrighton, 2001; Soars, Ring, & Wrighton, 2003; Vashishtha, Hawes, McCann, 
Ghosheh, & Hogg, 2002). Another commonly used detergent is brij58 (polyoxyethylene 
monocetyl ether). It is a non-ionic surfactant with high hydrophilic-lipophilic balance (HLB) and 
low critical micelle concentration (CMC) (Rai, Tan, & Michniak-Kohn, 2011). It is used to 
enhance membrane permeability to improve measurement of the activity of UGT. In this study 
we compared the effects of alamethicin and brij58 on UGT1A9 activity in microsomes. 
 
Selection of UGT and a Probe for Measuring its Activity 
 
UDP-glucuronosyltranserase (UGT) 1A9 is expressed in the liver, kidney and colon 
(McGurk, Brierley, & Burchell, 1998; Strassburg, Manns, & Tukey, 1998; Wooster et al., 1991). 
It conjugates planar and nonplanar phenols, anthraquinons, flavones, aliphatic alcohols, aromatic 
carboxylic acids and steroids (Liston et al., 2001). It metabolizes many drugs including 
propranolol, labetalol, acetaminophen, mycophenolic acid, ibuprofen and dapsone and 
endogenous compounds such as estrone, 4-hydroxyestrone and retinoic acid (Liston et al., 2001). 
An extensive literature search revealed that no study has investigated the activity of UGT1A9 
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during pregnancy. UGT1A9 glucuronidates a wide range of substrates (Ebner & Burchell, 1993) 
and is predominantly expressed in major metabolic tissues, liver and kidney, it is necessary to 
study its activity during pregnancy. Given that the activity of UGT1A1 has been reported to be 
increased by progesterone (Jeong et al., 2008) and the activity of UGT1A4 is increased by 
estrogen (Chen et al., 2009), it was of interest to evaluate the potential effects of estrogen and 
progesterone on the activity of UGT1A9.  
Mycophenolic acid (MPA), an active metabolite of mycophenolate mofetil (MMF), an 
immunosuppressant agent, acts by inhibition of inosine monophosphate dehydrogenase 
(IMPDH) in lymphocytes (Bullingham, Nicholls, & Kamm, 1998). Mycophenolic acid is mainly 
metabolized by UGT1A9 to the hydroxyl-β-glucuronide (MPAG) and to other two metabolites, 
MPA-acyl-glucuronide (AcMPAG) and MPA-phenyl-glucuronide (Picard, Ratanasavanh, 
Premaud, Le Meur, & Marquet, 2005). Most of the oral dose of MMF is excreted in the urine as 
MPAG (Bullingham et al., 1998). Mycophenolic acid serves as a good marker substrate of 
UGT1A9. 
The overall objective of this study is to set up a system for measuring the activity of 
UGT1A9 in human microsomes and hepatocytes. We hypothesized that treatment with 
alamethicin will lead to the highest measured activity of UGT1A9 in human liver microsomes, 
and that the expression of and activity of UGT1A9 will be increased by estradiol and 
progesterone in human hepatocytes. The specific aims of this study were a) to determine the 
effect of various surfactants (alamethicin and brij58) on the activity of UGT1A9 in microsomal 
systems; and b) to evaluate the effect of progesterone and estradiol on the expression and activity 
of UGT1A9 in primary cultures of human hepatocytes.  
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Table 1: Some endogenous and exogenous substrates for major human UGT isoforms 
UGT isoform Endogenous 
substrates 
Exogenous 
substrates 
References 
UGT1A1 Bilirubin, thyroxine Estradiol, paracetamol (Bock, 2010; Court, 
2005) 
UGT1A4 Androsterone Lamotrigine, 
imipramine, nicotine 
(Bock, 2010; Chen et 
al., 2009; Picard et al., 
2005) 
UGT1A9 Thyroxine, estrogens Mycophenolic acid, 
propofol, paracetamol 
(Bock, 2010; Court, 
2005; Radominska-
Pandya et al., 1999) 
UGT2B4 Androsterone, bile 
acids, arachidonic 
acid 
Fibrates (Bock, 2010; Court, 
2005; Radominska-
Pandya et al., 1999) 
UGT2B7 4-hydroxyesterone, 
progesterone, 
retinoids 
Morphine, zidovudine (Bock, 2010; Court, 
2005; Radominska-
Pandya et al., 1999) 
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2.0  MATERIALS AND METHODS 
 
2.1 CHEMICALS 
 
Mycophenolic acid (MPA), mycophenolic acid glucuronide (MPAG), uridine 5’ diphospho-
glucurinic acid (UDPGA), brij58, rifampicin, testosterone, saccharolactone, magnesium chloride 
(MgCl2) and dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis, MO). 
Alamethicin was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Bovine 
serum albumin (BSA) was purchased from Fluka (Buchs, Switzerland). 6β-hydroxytestosterone 
was purchased from Steraloids (Waltham, MA). Reagents for real time PCR were purchased 
from Promega (Madison, WI). Methanol and water (HPLC Grade) were purchased from Thermo 
Fisher Scientific (Waltham, MA). All tissues were obtained from the liver tissue cell distribution 
system, from the Hepatocyte Transplantation Laboratory at the University of Pittsburgh 
(Pittsburgh, PA). 
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2.2 EVALUATION OF MPAG FORMATION IN HUMAN LIVER MICROSOMES 
 
2.2.1 Microsomal Preparation 
 
Microsomes were prepared by differential centrifugation as previously described 
(Charpentier et al., 1997). Briefly, liver tissues were homogenized with three volumes of 
homogenization buffer (50 mM Tris–HCl buffer, 1% KCl and 1mM EDTA, pH 7.4) 
using an electrical homogenizer (Polytron, Brinkmann Instruments, Westbury, NY). The 
homogenate was centrifuged at 10,000g for 20 minutes at 4°C. The supernatant was 
further centrifuged at 105,000g for 65 min at 4°C. The microsomes were reconstituted 
with 50mM Tris-HCl buffer containing 20% glycerol. Aliquots were stored at -80°C until 
used. The protein concentration was determined by the Lowry method (Lowry, 
Rosebrough, Farr, & Randall, 1951). 
 
2.2.2 Microsomal Incubation 
 
Glucuronidation of MPA was characterized as previously described (Picard et al., 2005) 
with some modifications. The reaction mixture consisted of 0.5 mg/ml microsomal 
proteins (prepared in Tris-HCl buffer), 0.1M Phosphate buffer (pH 7.4), brij58 (0.015% 
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w/v final concentration protein) or alamethicin (50 µg/mg protein), 10mM MgCl₂, 6mM 
saccharolactone, 0.05 to 2mM mycophenolic acid, and 2mM uridine 5`-
diphosphoglucuronic acid (UDPGA).  The final volume of the reaction mixture was 
500µl. Microsomes were preincubated in ice with buffer and brij58 or alamethicin for 15 
min. MgCl₂ and saccharolactone and MPA were added to the mixture and pre-incubated 
at 37°C. The microsomal incubation was warmed up to 37°C, and, to initiate the reaction, 
UDPGA was added and the entire mixture was incubated for 30 min at 37°C. The 
reaction was stopped by the addition 25µl of perchloric acid (24% v/v). After 
centrifugation, the supernatant was stored at -20°C, until analysis of MPAG by high 
performance liquid chromatography (HPLC). The concentrations of alamethicin and 
brij58 used based on the concentrations that provided maximal activation of UGT (Chang 
et al., 2009; Court et al., 2001; Soars et al., 2003). 
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2.3 EVALUATION OF THE EFFECT OF PROGESTERONE AND ESTRADIOL ON 
THE FORMATION OF MPAG IN HUMAN HEPATOCYTES  
 
2.3.1 Preparation of Human Hepatocytes 
 
Human hepatocytes were obtained from Hepatocyte Transplantation Laboratory at the University 
of Pittsburgh (Pittsburgh, PA). Hepatocytes were isolated by a three-step collagenase perfusion 
method (Strom et al., 1996). The viability of the cells used ranged from 80 to 91% as measured 
by a trypan blue exclusion test. Briefly, trypan blue (0.4%) and cell suspension were mixed and 
then placed on a hemocytometer. The cells were observed under a light microscopy and the 
number of living and dead cells was counted. For study purpose, cells were diluted to a final 
volume of 1×10⁶ cells/ml in hepatocyte medium. Hepatocytes were plated on Falcon 6-well 
culture plates previously coated with rat tail collagen at a density of 1.5×10⁶ cells, and 
maintained in hepatocytes maintenance medium (HMM, Lonza Walkersville, Inc.) supplemented 
with 0.1 µM insulin, 0.1 µM dexamethasone, 0.05% streptomycin, 0.05% amphotericin B and 
10% bovine calf serum. After allowing 4-6 h for the cells to attach, the medium was replaced 
with serum free medium (HMM+). Cells were maintained in culture at 37 °C in an atmosphere 
containing 5% CO₂ and 95% air. After 24 h in culture, unattached cells were removed by gentle 
agitation and the medium was changed every 24 hours. 
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2.3.2 Hepatocyte Incubation 
 
The concentrations of progesterone and estradiol were chosen based on their levels in subjects 
during the third trimester of pregnancy (Becker, 2001). Two days after plating, the cells were 
treated for four days with HMM+ containing rifampin (10 µM, estradiol (0.1, 1 µM), 
progesterone (1, 10 µM) or a combination of progesterone and estradiol at low and high 
concentrations. Stock solutions of progesterone and estradiol were prepared in DMSO. The final 
concentration of DMSO in the medium used for incubation was less than 0.1%. The cells were 
observed daily under microscope to monitor cell morphology and attachment. On the fifth day, 
the medium was changed and fresh HMM+ containing MPA (100 µM) or testosterone (250 µM) 
was added and incubated for 30 min. After the end of the incubation period, the media were 
collected into 1.5 ml Eppendorf tubes. Testosterone served as a positive control for assessment of 
the functional capacity of the hepatocytes as measured by CYP3A activity. Treatment of 
hepatocytes with rifampicin served as a positive control to document the responsiveness of the 
hepatocytes to external stimulus. Experiments were performed in duplicate in human hepatocytes 
from three different donors. The characteristics of human liver donors are listed in Table (2). 
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Table 2: Human liver donor Characteristics 
       Donor Sex Age Medical 
History 
Viability (%) 
HH1956 M ND Explanted liver 80 
HH1958 F ND Steatosis 80 
HH1962 F 62 Metastatic tumor 91 
       M, male; F, female; ND, no data 
 
2.3.3 UGT1A9 mRNA Expression in Human Hepatocytes 
  
Total RNAs were isolated using Trizol reagent (Invitrogen, Carlsbad, CA) and used as a template 
for cDNA synthesis. RNA concentration was determined by UV absorbance at 260/280 nm 
(µQuant Microplate 25 Spectrophotometer). RNA integrity was measured by 0.5 % agarose gel 
electrophoresis with ethidium bromide staining. The cDNA was prepared as previously described 
(Komoroski et al., 2004). RT-PCR was performed using TaqMan system and conditions 
designated by Assays on Demand, Gene Expression Products (Applied Biosystems, Foster City, 
CA). The primers sequences used were provided by Assays on Demand, Gene Expression assay 
ID Hs99999904_m1 to detect cyclophilin A and Hs02516855_sH to detect UGT1A9. The 
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mRNA expression levels were measured in triplicate and normalized to mRNA content of 
cyclophilin A. 
  
2.4 ANALYTICAL METHODOLOGY 
2.4.1 Testosterone Analysis 
Stock solution of 6β-hydroxytestosterone was prepared in methanol and further diluted with 
HMM and used for standard curve.  Standard curve samples and hepatocyte medium samples 
were treated with methanol and vortexed. The samples were centrifuged at 13000 rpm for 5 min. 
One hundred µl samples were injected on to high-pressure liquid chromatographic system 
(HPLC). Testosterone and 6β-hydroxytestosterone were analyzed using Alliance HPLC system 
(Waters, Milford, MA). A reverse phase Hibar® RT 250-4 pre-packed column (4.6_250 mm, 0.5 
µm) (Merck KGaA, Darmstadt, Germany) was used. The mobile phase consisted of 60% 
methanol: 40% water (v/v) and the run time were 20 minutes. The retention time for 6β-
hydroxytestosterone was 5 min. Empower 2 software was used for data acquisition and analysis. 
The standard curve was linear in the concentration range of 0.2 – 10 µg/ml for 6β-
hydroxytestosterone. Concentrations of the metabolites observed in all samples were within this 
concentration range. The coefficient of variation (CV %) for the assay was less than 6%.  
Mycophenolic acid glucuronide was analyzed on an Alliance HPLC system (Waters 
2695, Milford, MA) attached to a photodiode array detector (PDA, Waters 2998) set at 250 nm. 
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The mobile phase consisted of (A) 20 mM ammonium acetate in 95% water 5% (B) methanol, 
(C) 95% water 5% methanol and (D) acetonitrile. Various components were separated using a 
Symmetry® C18 (4.6×250 mm, 5µm) column and the retention time of MPAG was 8.8 min. The 
concentration of MPAG was determined from a linear standard curve of containing known 
concentrations of MPAG (0.0675-10µg/ml) (Figure 1). The coefficient of variation of this assay 
was less than 10% at all concentrations tested. 
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Figure 1: Standard curves of mycophenolic acid glucuronide (MPAG) 
a) Standard curve used for estimation of MPAG concentrations in human liver microsomes,  
b) Standard curve used for estimation of MPAG concentrations in primary culture human liver 
hepatocytes. 
 
 
 
2.5 STATISTICAL ANALYSIS 
 
The data were analyzed by Student’s t-test and one-way ANOVA using Microsoft Excel 
2007. The Michalis-Menton kinentic parameters, Km and Vmax, were determined by GraphPad 
Prism 5 software.  The results were considered statistically significant at p ≤ 0.05.  
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3.0  RESULTS 
3.1 VALIDATION 0F HEPATOCYTE FUNCTION 
The base line activity of CYP3A was greater than 0.5 µg/ml in all the cultures tested as measured 
by the formation of 6-β (OH) testosterone (Table 3).  In HH1956, rifampicin (10µM) increased 
6-β (OH) testosterone formation by twofold, but this increase wasn’t statistically significant 
(p=0.28) (Figure 2). In HH1958 and HH1962, rifampicin (10µM) significantly increased 6-β 
(OH) testosterone formation by two- (p=0.02) and fivefold (p=0.002) respectively, indicating the 
responsiveness of the hepatocytes to inducers (Figure 2).  
 
Table 3: Effect of rifampicin on the activity of CYP3A4 as measured by the formation of 6β-
hydroxytestosterone. Basal activity of greater than 0.5 µg/ml and a change in activity of at least 50% are 
considered acceptable. 
 
Liver no. 
Untreated 
            (µg/ml) 
Treated with 
10 µM rifampicin 
(µg/ml) 
 
Fold change 
 
P value 
 
HH1956 
 
0.84 
 
1.74 
 
2 
 
0.28 
 
HH1958 
 
3.8 
 
8.8 
 
2 
 
0.02 
 
HH1962 
 
1.5 
 
7.7 
 
5 
 
0.002 
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Figure 2: Effect of rifampicin on the activity of CYP3A  
Human liver hepatocytes prepared from donors indicated in the figure were treated with 
rifampicin (10µM) for 4 days. On the fifth day, fresh media including testosterone (250µM) were added 
and incubated for 30 min. After 30 min of incubation, aliquots of the media were removed and 
testosterone 6β-hydroxylase formation was determined as described in Materials and Methods section. 
Each value represents means of duplicate treatments.  Abbreviations: TST, testosterone; RIF, rifampicin; 
TST+RIF, incubation of testosterone in presence of rifampicin. (*) Significantly different from cells not 
treated with rifampicin (p ≤ 0.05) (Student’s t-test). 
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3.2 MICROSOMAL INCUBATION 
 
Using the standard incubation conditions described above, enzyme kinetic parameters for the 
formation of MPAG were determined in human liver microsomes treated with different 
surfactants. The formation of MPAG was consistent with Michaelis-Menton kinetics at the 
substrate concentrations used in the experiment (Figure 3). Treatment with alamethicin showed 
an increase in the formation rate of MPAG; however, we didn’t detect any statistical significance 
using one-way ANOVA test (p=0.16). Vmax following treatment with alamethicin was higher 
than following treatment with brij58; however, it was not significant (p=0.45) (Table 4). The Km 
values were relatively same for all treatments (Table 4). A two fold increase in Vmax with 
alamethacin and brij58 suggest that is better to use these surfactants with microsomes, when 
UGT1A9 activity is to be measured.  
 
Table 4: Kinetic parameters of MPA glucuronidation in alamethcin and brij58- pretreated mixture 
of human liver microsomes 
 Control Alamethicin Brij58 p-value (one-
way ANOVA) 
Vmax (nmol/min/mg 
protein) 
4137 11460 7193 0.45 
Km (µM) 9498 1185 1119 0.83 
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Human liver microsomes were preincubated with brij58 (0.015% w/v final concentration protein) or 
alamethicin (50 µg/mg protein) for 15 min. Different concentrations of mycophenolic acid were added to 
the mixture and incubated at 37°C. After 30 min of incubation, aliquots of the media were removed and 
mycophenolic acid glucuronide (MPAG) formation rate was determined by high performance liquid 
chromatography (HPLC) as described in the materials and methods section. Data were analyzed by one-
way ANOVA to detect statistical significance. Each value represents the means of duplicate treatments 
(n=2). 
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Figure 3: Effect of alamethicin and brij 58 on the    
rate of formation of MPAG  
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3.3 HUMAN HEPATOCYTE INCUBATION 
 
The potential regulation of UGT1A9 by estradiol and progesterone was examined using primary 
cultures of human hepatocytes. The formation rate of MPAG served as a measure of the activity 
of UGT1A9. Figure 4 shows the effect of estradiol 0.1 µM /progesterone 1µM, estradiol (0.1, 1 
µM), progesterone (1, 10 µM) and estradiol 1 µM/ progesterone 10 µM on the activity of 
UGT1A9 as measured by the formation of MPAG. Incubation with estradiol 1 µM/ progesterone 
10 µM and estradiol 0.1 µM /progesterone 1µM increased MPAG rate formation by 40% and 
33%, respectively compared to the untreated cells. Combination of estradiol and progesterone 
showed the maximum effect over incubation of these compounds separately. 
 Although incubation of combination of estradiol and progesterone showed the highest 
increase, there was no statistical significant as determined by one-way ANOVA (p=0.99).   
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Figure 4: Effect of estradiol and progesterone on mycophenolic acid glucuronidation 
Human liver hepatocytes were incubated with estradiol and progesterone or vehicle control for four days. 
On the fifth day, the media were changed to contain mycophenolic acid (100µM) and incubated for 30 
min. After 30 min, the media were collected and concentrations of mycophenolic acid glucuronide were 
determined by HPLC. Data were analyzed by one-way ANOVA to detect statistical significance. Each 
value represents the mean of four treatments (n=4). EST, estradiol; PROG, progesterone 
 (all units are in µM). 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
Control EST 
O.1/PROG 
1 
EST 
1/PROG 
10 
EST 0.1 EST 1 PROG 1 PROG 10 M
PA
G
 F
or
am
at
io
n 
R
at
e 
 
(%
 o
f c
on
tr
ol
) 
 25 
 
3.4 EFFECT OF ESTRADIOL AND PROGESTERONE ON UGT1A9 MRNA 
EXPRESSION 
 
For further analysis of the effect of the hormones on the expression of UGT1A9, mRNA was 
examined using real time polymerase chain reaction (PCR). Figure 5 summarizes the effect of 
progesterone and estradiol on the expression of UGT1A9. Addition of estradiol 0.1 µM/ 
progesterone 1 µM did not have any effect on the expression of UGT1A9 mRNA. Treatment the 
human hepatocytes with estradiol 1 µM/ progesterone 10 µM increased the expression by 2.7-
fold, but this increase was not significant (p=0.25). 
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Figure 5: Effect of estradiol and progesterone on the UGTA1A9 mRNA expression 
Human liver hepatocytes were treated with estradiol 0.1µM+ progesterone 1 µM and estradiol 1 µM+ 
progesterone 10 µM or vehicle control for five days. On the fifth day of treatment, mRNA levels were 
determined by RT-PCR and normalized with cyclophilin A results represent percentage changes relative 
to the vehicle control. Data were analyzed by one-way ANOVA detect statistical significant. Each value 
represents the means of duplicate treatment (n=2). 
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4.0  DISCUSSION  
 
Glucuronidation plays a major role in metabolizing various endogenous and xenobiotic 
molecules (Radominska-Pandya et al., 1999). Many factors have been shown to affect 
glucuronidation including disease states, age, diet, gender, cigarette smoking, alcohol 
consumption, ethnicity, genetic polymorphism, drug-drug interaction (Liston et al., 2001; Miners 
et al., 2004). Pregnancy is one important factor that has been reported to affect drug metabolism. 
Pregnancy is accompanied by many physiological changes that can alter the metabolism of drugs 
being taken during pregnancy (Anderson, 2005). Only a few studies have been conducted to 
determine changes in drug metabolism during pregnancy (Chen et al., 2009; Jeong et al., 2008; 
Miners et al., 1986). 
Understanding physiologic changes during pregnancy and how these changes affect drug 
disposition could avoid sub therapeutic or over dosing of drugs in the pregnant subject. Most 
studies to date have been carried out in animal models and the results cannot be extrapolated to 
humans. Thus, establishing a human-based system such as human liver hepatocytes and human 
liver microsomes is important to evaluate the mechanism behind altered activity of UGTs during 
pregnancy. This study describes the first step in that direction. 
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UGT1A9 is an important enzyme involved in conjugation of many endogenous and 
exogenous molecules (Liston et al., 2001; Radominska-Pandya et al., 1999).  The first objective 
of this study was to optimize the conditions to measure the activity of UGT1A9 in human liver 
microsomes. Studying UGTs requires the use of surfactant to permeabilize the membrane to 
allow interaction of the substrate with the active site of the enzyme (Banhegyi, Garzo, Fulceri, 
Benedetti, & Mandl, 1993). The most common detergents used to evaluate UGTs are alamethicin 
and brij58. We evaluated the effect of alamethecin and brij58 on the formation of MPAG in 
hepatic microsomes. The results showed that alamethecin and brij tended to give higher activity 
estimates for UGT1A , which is in agreement with previous results (Soars et al., 2003).  
In the current study, we hypothesized that estradiol and progesterone at high 
concentrations seen in pregnancy will have a regulatory effect on the expression of UGT1A9. 
Thus, the second objective was to evaluate the changes in the activity of UGT1A9 in human 
hepatocytes following treatment of human hepatocytes with estradiol and progesterone to mimic 
physiologic conditions of pregnancy. We used MPA as a substrate to determine the activity of 
UGT1A9. The data presented here show that primary cultures of human hepatocytes were able to 
metabolize MPA to MPAG. The data show that a combination of estradiol and progesterone at 1 
and 10 µM respectively increase the MPAG rate formation by 40% (Figure 4). Real-time RT-
PCR results confirmed that estradiol and progesterone together increased UGT1A9 mRNA 
expression by 2.7-fold. However, there was no significant difference in the increase in the 
MPAG rate formation and UGT1A9 mRNA expression. Estradiol (0.1, 1 µM) and progesterone 
(1, 10 µM) alone showed an increase in the MPAG formation rate only minimally (13 - 22%) 
(Figure 5). The findings suggested that both progesterone and estradiol together do not have 
major effects on the activity of UGT1A9 under the conditions tested.  
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It has been hypothesized that the dramatic increase in female hormones contributes in 
alteration of drug metabolism in pregnant women (Jeong et al., 2008). Female hormones have 
been suggested to have different functions from their primary functions as gonadal hormones at 
high concentrations seen in pregnancy (Jeong et al., 2008). Studies have shown that estradiol and 
progesterone regulate hepatic metabolic enzyme expression and transporters through pregnane X 
receptors (PXR) and estrogen receptors (ERα) (Wang et al., 2006; Yamamoto et al., 2006). 
Using ERα- transfected HepG2 cells treated with different female sex hormones has revealed 
that UGT1A1 expression can be up-regulated by high concentration of progesterone through 
PXR (Jeong et al., 2008). The effect of estradiol and progesterone on the UGTs enzymes has 
been intensively studied for lamotrigine. Lamotrigine clearance increased when combined with 
oral contraceptives (Christensen et al., 2007; Sabers, Buchholt, Uldall, & Hansen, 2001; Sabers, 
Ohman, Christensen, & Tomson, 2003). This increase in lamotrigine clearance has been linked 
to an increase in the concentration of female hormones (Chen et al., 2009). A study has reported 
that estrogen containing contraceptives were responsible for increased clearance of lamotrigine 
and not progesterone (Reimers, Helde, & Brodtkorb, 2005). An earlier clinical study conducted 
in pregnant women at the third trimester has shown that the clearance of paracetamol was 
increased in pregnant women compared to the controls (Miners et al., 1986). Another study has 
shown an increased in bilirubin, a UGT1A1 substrate, glucuronidation after treatment of 3-MC 
(Ritter et al., 1999). In contrast, another study reported that no induction was noted in 
glucuronidation mediated by UGT1A1 after treatment of 3-MC (Li, Hartman, Lu, Collins, & 
Strong, 1999). These contradictory results outline the difficulty of studying UGT enzyme family 
due to complex regulatory mechanisms and some factors that should be taken in consideration 
such as enzyme latency (Banhegyi et al., 1993; Jeong et al., 2008). Our observations indicate that 
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unlike UGT1A1 and UGT1A4, UGT1A9 is unlikely to be affected by high concentrations of 
progesterone and estradiol. 
 Progesterone and estradiol concentrations in this study were chosen based on their levels 
at the third trimester. The physiological levels of progesterone and estradiol are 0.1 and 1 µM, 
respectively (Becker, 2001). It is known that liver is the major metabolism organ receiving about 
30% of cardiac output (Jeong et al., 2008). Progesterone and estradiol concentrations in liver are 
reported to be tenfold (Carlson, Brandes, Pomper, & Katzenellenbogen, 1988) and threefold 
(Schleicher, Tauber, Louton, & Schunack, 1998) respectively, higher than the hormone levels in 
the blood (Jeong et al., 2008). Therefore, selection of 10 µM progesterone and 1 µM estradiol 
will simulate levels observed in pregnant women’s livers (Jeong et al., 2008).  
There are other factors such as drug transporters and polymorphism that can also alter the 
pharmacokinetics of drugs during pregnancy. Glucuronide conjugates typically require 
transporters to get out of the cells (Williams & Lemke, 2002). Studies have shown that 
pregnancy can also alter drug transporters (Meyer zu Schwabedissen et al., 2005; Wang et al., 
2006). A study has reported an increased in the Bcrp expression in the liver of pregnant mice at 
mid-gestational ages, suggesting that the systemic exposure of drugs could be affected due to 
changes in the activity of transporters during pregnancy (Wang et al., 2006). Thus, it is possible 
the alteration in drug transporters activity could also influence the elimination of glucuronides. 
Genetic polymorphism has been reported in the UGT families (Testa & Krämer, 2010). Crigler-
najar and Gilbert syndrome are caused by the mutations in UGT1A1 (Testa & Krämer, 2010). 
Genetic polymorphism is another factor that plays a role in the regulation of the activity of 
UGTs.  The UGT1A9 isoforms has been reported to have genetic polymorphism (Levesque et 
al., 2007). 
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Some limitations of this study must be taken in consideration while interpreting the 
results. This study was conducted in a small number of hepatocytes that, due to variation in 
activity, may not lead to statistically significant activity differences. Also, the effect of 
transporters was not investigated which may not be ruled out as a potential factor that changes 
drug metabolism during pregnancy. 
Future studies to determine the change in drug transporters is highly recommended. Also, 
further studies should be conducted to evaluate all the major UGTs isoforms to overcome the 
ambiguity that arises from limited understanding a single glucuronidation pathway. Screening for 
genetic polymorphism for UGT1A9 in the hepatocytes is recommended in the future to exclude 
any effect that might interfere with the accuracy of the results. 
In conclusion, we have shown that estradiol and progesterone do not have the potential to 
regulate the expression of UGT1A9 using primary cultures of human hepatocytes under the 
conditions tested. In addition, we have shown that alamethicin shows no superiority over brij58 
in the activation effect for UGT1A9.   
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